Lilly reported 48% second-quarter revenue growth and 33% non-GAAP EPS growth, which included acquisition charges. Management raised the midpoints of its 2026 guidance to $86 billion in revenue and $36 per share in non-GAAP EPS. Shares rose 5% on Aug. 5.
Lilly's strong leadership in weight-loss drugs should drive industry-leading growth, given its approved drugs and well-positioned next-generation weight-loss drugs in the pipeline.
The risks to success for Kisunla remain high because of bottlenecks in patient diagnosis, required scans and monitoring, and competition, particularly from Eisai/Biogen (Leqembi) and Roche (pipeline drug trontinemab).
|
Metric
|
LLY
|
NVO
|
MRK
|
|---|---|---|---|
Price/Earnings (Normalized) | 40.22 | 11.13 | 42.36 |
Price/Book Value | 31.13 | 5.88 | 8.00 |
Price/Sales | 13.32 | 3.88 | 5.07 |
Price/Cash Flow | 32.26 | 9.29 | 15.22 |
|
Metric
|
LLY
|
NVO
|
MRK
|
|---|---|---|---|
Return on Assets (Normalized) | 24.05% | 21.31% | 6.27% |
Return on Equity (Normalized) | 105.62% | 59.99% | 16.68% |
Return on Invested Capital (Normalized) | 39.55% | 34.79% | 9.82% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Johnson & Johnson
JNJ
| LOCK|?tR>k<B | LOCK|zW! | $632B | |||
| AbbVie Inc
ABBV
| LOCK|$@<tL% | LOCK|Grp | $442B | |||
| Roche Holding AG ADR
RHHBY
| LOCK|C<$P%JhV | LOCK|M?^ | $350B | |||
| Merck & Co Inc
MRK
| LOCK|>s?$mZf | LOCK|jX | $335B | |||
| Novartis AG ADR
NVS
| LOCK|&$qw!&s@ | LOCK|nN | $289B | |||
| AstraZeneca PLC
AZN
| LOCK|>@?M@zFF | LOCK|#H | $243B | |||
| Amgen Inc
AMGN
| LOCK|q@VxCG^s | LOCK|<Vd | $227B | |||
| Novo Nordisk AS ADR
NVO
| LOCK|Z^?Fhd | LOCK|$? | $200B | |||
| Gilead Sciences Inc
GILD
| LOCK|$^Bn@! | LOCK|zh | $172B |
United States